
ViiV Healthcare Reports Dovato Matches Biktarvy Efficacy in Landmark HIV Study
ViiV Healthcare’s 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy in first-of-its-kind head-to-head study in treatment-naïve adults living with HIV ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, announced data to be presented this…














